Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of selinexor in combination with CD19/CD22 bispecific chimeric antigen receptor (CAR) T cell therapy for relapsed/refractory diffuse large B-cell lymphoma: A single-center, retrospective, real-world study

He-nan Wang, Xin-di Liu, Yuan-zheng Liang, Liang Wang, Jia Cong

Blood (2025) 146 (Supplement 1): 3715.

https://doi.org/10.1182/blood-2025-3715

Published: 2025

Journal Articles

Impact of autoimmune hemolytic anemia on prognosis in chronic lymphocytic leukemia patients: A comprehensive retrospective analysis

Liang Wang, Yuting Yan, Lugui Qiu, Tingyu Wang, Shuhua Yi

Blood (2025) 146 (Supplement 1): 2126.

https://doi.org/10.1182/blood-2025-2126

Published: 2025

Journal Articles

Efficacy and safety analysis of CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma after failure of bispecific antibody treatment

Fu-li Li, Jia Cong, Liang Wang

Blood (2025) 146 (Supplement 1): 1941.

https://doi.org/10.1182/blood-2025-1941

Published: 2025

Journal Articles

Efficacy and safety of orelabrutinib, obinutuzumab, and lenalidomide in previously untreated marginal zone lymphoma: Preliminary results from a prospective, single-arm, multicenter, Phase II study

Wei Wang, Yueying Mao, Jing Ruan, Huacong Cai, Jin Ye, JunLi Chen, Liang Wang, Wenrong Huang, Yan Zhang, Jian Li

Blood (2025) 146 (Supplement 1): 5383.

https://doi.org/10.1182/blood-2025-5383

Published: 2025

Journal Articles

Impact of systemic high-dose MTX and BTK inhibitors on outcomes in vitreoretinal lymphoma: A multicenter retrospective analysis

Jing Gao, Lu Zhang, Liang Wang

Blood (2025) 146 (Supplement 1): 5467.

https://doi.org/10.1182/blood-2025-5467

Published: 2025

Journal Articles

CD19/CD22 bispecific CAR-t cell therapy for relapsed/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial

Xin-di Liu, He-nan Wang, Yuan-zheng Liang, Jia Cong, Liang Wang

Blood (2025) 146 (Supplement 1): 570.

https://doi.org/10.1182/blood-2025-570

Published: 2025

Journal Articles

Upfront maintenance therapy improves the prognosis of patients with diffuse large B-cell lymphoma in the era of novel agents: A multicenter retrospective study

Liwei Lv, Liu Zixian, Yan-ying Wang, Jie Li, He-Bing Zhou, Li Hong Li, Zhenling Li, Liang Wang

Blood (2025) 146 (Supplement 1): 7227.

https://doi.org/10.1182/blood-2025-7227

Published: 2025

Journal Articles

Effectiveness and safety of polatuzumab vedotin in real-world clinical practice in Chinese patients with diffuse large B-cell lymphoma (POLAREAL): An interim analysis from a prospective, multicenter, observational registry study

Blood (2025) 146 (Supplement 1): 6293.

https://doi.org/10.1182/blood-2025-6293

Published: 2025

Journal Articles

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

Blood (2025) 146 (Supplement 1): 1878.

https://doi.org/10.1182/blood-2025-1878

Published: 2025

Journal Articles

ΔSUV max between Baseline and Interim 18 f-FDG PET/CT Scans Could Better Assess the Early Response to Induction Therapy and Identify False-Positive Findings at Interim PET/CT in Extranodal NK/T-Cell Lymphoma

Lijie Zeng, Lei Yang, Mei Li, Liang Wang

Blood (2024) 144 (Supplement 1): 3073.

https://doi.org/10.1182/blood-2024-210595

Published: 2024

Journal Articles

A Phase Ib/II Clinical Trial of Linperlisib Combined with Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-Cell Lymphoma: Analysis of the Phase Ib Part

Lei Yang, Xin Li, Jia Cong, Liang Wang

Blood (2024) 144 (Supplement 1): 6413.

https://doi.org/10.1182/blood-2024-207469

Published: 2024

Journal Articles

Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)

Xin Li, Jia Wei, Dong-feng Zeng, Shu-nan Qi, Bingzong Li, Wei Guo, Li Wang, Yajun Li, Xudong Zhang, Yong Yang, Shukai Qiao, Yan Zeng, Yunfei Song, Jing-wen Wang, Jian-min Ma, Liang Wang

Blood (2024) 144 (Supplement 1): 4418.

https://doi.org/10.1182/blood-2024-206489

Published: 2024

Journal Articles

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

Blood (2024) 144 (Supplement 1): 4450.

https://doi.org/10.1182/blood-2024-209224

Published: 2024

Journal Articles

Mitoxantrone Hydrochloride Liposome Combined with Polatuzumab Vedotin and Dexamethasone (MPD) Is Highly Effective and Well Tolerated As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Xin-di Liu, Jia Cong, Lei Yang, Jing Yang, Liang Wang

Blood (2024) 144 (Supplement 1): 6475.

https://doi.org/10.1182/blood-2024-209754

Published: 2024

Journal Articles

BR105 Is a Novel Anti-Sirpα Monoclonal Antibody That Demonstrates a Favorable Safety Profile and Potent Anti-Tumor Efficacy in Patients with Relapsed/Refractory Lymphoid Malignancies: Preliminary Results from a Phase I Study

Ningjing Lin, Tingting Du, Hui Zhou, Yajun Li, Liang Wang, Xiaomeng Dong, Haochuan Zheng, Jingtao Lu, Mi Tang, Jihua Wu, Wei Zhu, Yuqin Song, Jun Zhu

Blood (2024) 144 (Supplement 1): 4175.

https://doi.org/10.1182/blood-2024-206674

Published: 2024

Journal Articles

A Phase 2 Multicenter Study of Pegaspargase in Combination with Gemcitabine, Etoposide, Mitoxantrone Hydrochloride Liposome, and Dexamethasone (P-GEMD) for Newly Diagnosed Early Non-Upper Aero-Digestive Tract or Advanced Stage Extranodal NK/T Cell Lymphoma

Jinhua Liang, Hao-Rui Shen, Hua Yin, Jiazhu Wu, Yue Li, Li Wang, Jianyong Li, Liang Wang, Xu Wei

Blood (2024) 144 (Supplement 1): 6396.

https://doi.org/10.1182/blood-2024-203071

Published: 2024

Journal Articles

Polatuzumab Vedotin-Based Regimens As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Xin-di Liu, Jia Cong, Jing Yang, Liang Wang

Blood (2024) 144 (Supplement 1): 6545.

https://doi.org/10.1182/blood-2024-203066

Published: 2024

Journal Articles

Orelabrutinib with or without Anti-CD20 Monoclonal Antibodies Is Highly Effective and Well Tolerated As First-Line Therapy for Marginal Zone B Cell Lymphoma

Na Yao, Xin Li, Jing Yang, Jia Cong, Liang Wang

Blood (2024) 144 (Supplement 1): 6541.

https://doi.org/10.1182/blood-2024-203548

Published: 2024

Journal Articles

Rapid Step-up Dosing Schedule of Glofitamab Is Feasible for Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Jing Yang, Liang Wang

Blood (2024) 144 (Supplement 1): 6540.

https://doi.org/10.1182/blood-2024-202904

Published: 2024

Journal Articles

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Shenmiao Yang, Huayuan Zhu, Ru Feng, Xutao Guo, Ting Niu, Jian-Qing Mi, Zhenling Li, Qianqian Ju, Liru Wang, Yujun Dong, Bingjie Wang, Liang Wang, Wanling Sun, Fang Fang, Liping Su, Yu Zhao, Xiaojun Huang, Jianyong Li

Blood (2024) 144 (Supplement 1): 6773.

https://doi.org/10.1182/blood-2024-206560

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Efficacy and safety of selinexor in combination with CD19/CD22 bispecific chimeric antigen receptor (CAR) T cell therapy for relapsed/refractory diffuse large B-cell lymphoma: A single-center, retrospective, real-world study

Impact of autoimmune hemolytic anemia on prognosis in chronic lymphocytic leukemia patients: A comprehensive retrospective analysis

Efficacy and safety analysis of CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma after failure of bispecific antibody treatment

Efficacy and safety of orelabrutinib, obinutuzumab, and lenalidomide in previously untreated marginal zone lymphoma: Preliminary results from a prospective, single-arm, multicenter, Phase II study

Impact of systemic high-dose MTX and BTK inhibitors on outcomes in vitreoretinal lymphoma: A multicenter retrospective analysis

CD19/CD22 bispecific CAR-t cell therapy for relapsed/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial

Upfront maintenance therapy improves the prognosis of patients with diffuse large B-cell lymphoma in the era of novel agents: A multicenter retrospective study

Effectiveness and safety of polatuzumab vedotin in real-world clinical practice in Chinese patients with diffuse large B-cell lymphoma (POLAREAL): An interim analysis from a prospective, multicenter, observational registry study

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

ΔSUV max between Baseline and Interim 18 f-FDG PET/CT Scans Could Better Assess the Early Response to Induction Therapy and Identify False-Positive Findings at Interim PET/CT in Extranodal NK/T-Cell Lymphoma

A Phase Ib/II Clinical Trial of Linperlisib Combined with Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-Cell Lymphoma: Analysis of the Phase Ib Part

Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

Mitoxantrone Hydrochloride Liposome Combined with Polatuzumab Vedotin and Dexamethasone (MPD) Is Highly Effective and Well Tolerated As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma

BR105 Is a Novel Anti-Sirpα Monoclonal Antibody That Demonstrates a Favorable Safety Profile and Potent Anti-Tumor Efficacy in Patients with Relapsed/Refractory Lymphoid Malignancies: Preliminary Results from a Phase I Study

A Phase 2 Multicenter Study of Pegaspargase in Combination with Gemcitabine, Etoposide, Mitoxantrone Hydrochloride Liposome, and Dexamethasone (P-GEMD) for Newly Diagnosed Early Non-Upper Aero-Digestive Tract or Advanced Stage Extranodal NK/T Cell Lymphoma

Polatuzumab Vedotin-Based Regimens As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Orelabrutinib with or without Anti-CD20 Monoclonal Antibodies Is Highly Effective and Well Tolerated As First-Line Therapy for Marginal Zone B Cell Lymphoma

Rapid Step-up Dosing Schedule of Glofitamab Is Feasible for Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only